Citations (46)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Brian Schwartz, Zachary D. Cohen, Julian A. Rubel, Dirk Zimmermann, Werner W. Wittmann & Wolfgang Lutz. (2021) Personalized treatment selection in routine care: Integrating machine learning and statistical algorithms to recommend cognitive behavioral or psychodynamic therapy. Psychotherapy Research 31:1, pages 33-51.
Read now
Read now
Maurizio Benucci, Roberto Ravasio & Arianna Damiani. (2017) Mean cost per number needed to treat with tocilizumab plus methotrexate versus abatacept plus methotrexate in the treatment of rheumatoid arthritis in patients previously treated with methotrexate. ClinicoEconomics and Outcomes Research 9, pages 403-410.
Read now
Read now
Glenn Clark. (2015) Evidence-Based Pharmacologic Approaches for Chronic Orofacial Pain. Journal of the California Dental Association 43:11, pages 643-654.
Read now
Read now
Machaon Bonafede, Barbara H. Johnson, Nicole Princic, Neel Shah & David J. Harrison. (2015) Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis. Journal of Medical Economics 18:5, pages 376-389.
Read now
Read now
Vernon F. Schabert, Crystal Watson, Shravanthi R. Gandra, Seth Goodman, Kathleen M. Fox & David J. Harrison. (2012) Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States. Journal of Medical Economics 15:2, pages 264-275.
Read now
Read now
E. Turkstra, S.-K. Ng & P.A. Scuffham. (2011) A mixed treatment comparison of the short-term efficacy of biologic disease modifying anti-rheumatic drugs in established rheumatoid arthritis. Current Medical Research and Opinion 27:10, pages 1885-1897.
Read now
Read now
JCF van Luijn, M Danz, JWJ Bijlsma, FWJ Gribnau & HGM Leufkens. (2011) Post-approval trials of new medicines: widening use or deepening knowledge? Analysis of 10 years of etanercept. Scandinavian Journal of Rheumatology 40:3, pages 183-191.
Read now
Read now
LE Kristensen, AK Jakobsen, EM Bartels, P Geborek, H Bliddal, T Saxne, B Danneskiold-Samsøe & R Christensen. (2011) The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials. Scandinavian Journal of Rheumatology 40:1, pages 1-7.
Read now
Read now
Inka Brockhausen & Tassos P Anastassiades. (2008) Inflammation and arthritis: perspectives of the glycobiologist. Expert Review of Clinical Immunology 4:2, pages 173-191.
Read now
Read now
V. Brodszky, M. Pentek & L. Gulacsi. (2008) Efficacy of adalimumab, etanercept, and infliximab in psoriatic arthritis based on ACR50 response after 24 weeks of treatment. Scandinavian Journal of Rheumatology 37:5, pages 399-400.
Read now
Read now
Articles from other publishers (36)
Jean-Marie Berthelot & Christelle Darrieutort-Laffite. (2023) Les poussées seulement transitoires des rhumatismes inflammatoires chroniques ne devraient plus être scotomisées. Revue du Rhumatisme 90:6, pages 685-688.
Crossref
Crossref
Ryan M Hum, Pauline Ho, Nisha Nair, Meghna Jani, Ann W Morgan, John D Isaacs, Anthony G Wilson, Kimme L Hyrich, Darren Plant, Anne Barton, H Gaston, D Mulherin, T Price, T Sheeran, V Chalam, S Baskar, P Emery, A Morgan, M Buch, S Bingham, S O’Reilly, L Badcock, M Regan, T Ding, C Deighton, G Summers, N Raj, R Stevens, N Williams, J Isaacs, P Platt, D Walker, L Kay, B Griffiths, W -F Ng, P Peterson, A Lorenzi, H Foster, M Friswell, B Thompson, M Lee, I Griffiths, A Hassell, P Dawes, C Dowson, S Kamath, J Packham, M Shadforth, A Brownfield, R Williams, C Mukhtyar, B Harrison, N Snowden, S Naz, J Ledingham, R Hull, F McCrae, A Thomas, S Young Min, R Shaban, E Wong, C Kelly, C Heycock, J Hamilton, V Saravanan, G Wilson, D Bax, L Dunkley, M Akil, R Tattersall, R Kilding, S Till, J Boulton, T Tait, M Bukhari, J Halsey, L Ottewell, C Buckley, D Situnayake, D Carruthers, K Grindulis, F Khatack, S Elamanchi, K Raza, A Filer, R Jubb, R Abernathy, M Plant, S Pathare, F Clarke, S Tuck, J Fordham, A Paul, M Bridges, A Hakim, D O’Reilly, V Rajagopal, S Bhagat, C Edwards, P Prouse, R Moitra, D Shawe, A Bamji, P Klimiuk, A Bowden, W Mitchell, I Bruce, A Barton, R Gorodkin, P Ho, K Hyrich, W Dixon, A Rai, G Kitas, N Erb, R Klocke, K Douglas, A Pace, R Sandhu, A Whallett, F Birrell, M Allen, K Chaudhuri, C Chattopadhyay, J McHale, A Jones, A Gupta, I Pande, I Gaywood, P Lanyon, P Courtney, M Doherty, H Chinoy, T O’Neill, A Herrick, A Jones, R Cooper, R Bucknall, C Marguerie, S Rigby, N Dunn, S Green, A Al-Ansari, S Webber, N Hopkinson, C Dunne, B Quilty, B Szebenyi, M Green, M Quinn, A Isdale, A Brown, B Saleem, A Samanta, P Sheldon, W Hassan, J Francis, A Kinder, R Neame, A Moorthy, W Al-Allaf, A Taggart, K Fairburn, F McKenna, M Green, A Gough, C Lawson, M Piper, E Korendowych, T Jenkinson, R Sengupta, A Bhalla, N McHugh, D Bond, R Luqmani, B Bowness, P Wordsworth, J David, W Smith, D Mewar, E Tunn, K Nelson, T Kennedy, J Nixon, A Woolf, M Davis, D Hutchinson, A Endean, D Coady, D Wright, C Morley, G Raftery, C Bracewell, L Kidd, I Abbas, C Filer & G Kallarackal. (2023) Non-trough adalimumab and certolizumab drug levels associated with a therapeutic EULAR response in adherent patients with rheumatoid arthritis. Rheumatology 62:6, pages 2090-2097.
Crossref
Crossref
Jean-Marie Berthelot & Christelle Darrieutort-Laffite. (2023) Transient flares (attacks) of inflammatory arthritis should be more considered. Joint Bone Spine 90:3, pages 105517.
Crossref
Crossref
Jie Wu, Kexin Wang, Qinwen Liu, Yi Li, Yingying Huang, Yujie Liu, Jieqi Cai, Chuanhui Yin, Xiaowei Li, Hailang Yu, Wei Meng, Handuo Wang, Aiping Lu, Yazi Li & Daogang Guan. (2022) An Integrative Pharmacology Model for Decoding the Underlying Therapeutic Mechanisms of Ermiao Powder for Rheumatoid Arthritis. Frontiers in Pharmacology 13.
Crossref
Crossref
Roberto Ravasio, Silvia Antonelli, Alessia Maiorino, Antonio Costanzo & Serena Losi. (2019) Cost per responder for ixekizumab and other biologic drugs approved for the treatment of moderate-to-severe plaque psoriasis in Italy. Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish 2019, pages 228424031882228.
Crossref
Crossref
Karen Smith, Su Golder, Abeed Sarker, Yoon Loke, Karen O’Connor & Graciela Gonzalez-Hernandez. (2018) Methods to Compare Adverse Events in Twitter to FAERS, Drug Information Databases, and Systematic Reviews: Proof of Concept with Adalimumab. Drug Safety 41:12, pages 1397-1410.
Crossref
Crossref
Roberto Ravasio, Silvia Antonelli, Veronica Rogai, Walid Fakhouri, Jean Philippe Capron & Serena Losi. (2018) Mean cost per number needed to treat of baricitinib versus adalimumab in the treatment of rheumatoid arthritis in Italy. Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish 2018, pages 228424031879095.
Crossref
Crossref
Jasvinder A Singh, Alomgir Hossain, Elizabeth Tanjong Ghogomu, Amy S Mudano, Lara J Maxwell, Rachelle Buchbinder, Maria Angeles Lopez-Olivo, Maria E Suarez-Almazor, Peter Tugwell & George A Wells. (2017) Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis. Cochrane Database of Systematic Reviews 2017:3.
Crossref
Crossref
Tanja Schjødt Jørgensen, Carl Turesson, Meliha Kapetanovic, Martin Englund, Aleksandra Turkiewicz, Robin Christensen, Henning Bliddal, Pierre Geborek & Lars Erik Kristensen. (2017) EQ-5D utility, response and drug survival in rheumatoid arthritis patients on biologic monotherapy: A prospective observational study of patients registered in the south Swedish SSATG registry. PLOS ONE 12:2, pages e0169946.
Crossref
Crossref
Anders Gülfe, Johan K. Wallman & Lars Erik Kristensen. (2016) EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden. Arthritis Research & Therapy 18:1.
Crossref
Crossref
Jasvinder A Singh, Alomgir Hossain, Elizabeth Tanjong Ghogomu, Amy S Mudano, Peter Tugwell & George A Wells. (2016) Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA). Cochrane Database of Systematic Reviews 2016:11.
Crossref
Crossref
Glenn T. Clark, Mariela Padilla & Raymond Dionne. (2016) Medication Treatment Efficacy and Chronic Orofacial Pain. Oral and Maxillofacial Surgery Clinics of North America 28:3, pages 409-421.
Crossref
Crossref
Alberto Batticciotto, Roberto Ravasio, Marta Riva & Piercarlo Sarzi-Puttini. (2016) Efficacy and Treatment Costs of Monotherapy with bDMARDs in the Treatment of Rheumatoid Arthritis in Patients Intolerant to or Inappropriate to Continue Treatment with Methotrexate. Advances in Therapy 33:8, pages 1360-1373.
Crossref
Crossref
Jasvinder A Singh, Alomgir Hossain, Elizabeth Tanjong Ghogomu, Ahmed Kotb, Robin Christensen, Amy S Mudano, Lara J Maxwell, Nipam P Shah, Peter Tugwell & George A Wells. (2016) Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. Cochrane Database of Systematic Reviews 2016:5.
Crossref
Crossref
Xin Xu, Liwei Zheng, Qin Bian, Liang Xie, Wenlong Liu, Gehua Zhen, Janet L Crane, Xuedong Zhou & Xu Cao. (2015) Aberrant Activation of TGF-β in Subchondral Bone at the Onset of Rheumatoid Arthritis Joint Destruction. Journal of Bone and Mineral Research 30:11, pages 2033-2043.
Crossref
Crossref
David L Scott, Fowzia Ibrahim, Vern Farewell, Aidan G O’Keeffe, Margaret Ma, David Walker, Margaret Heslin, Anita Patel & Gabrielle Kingsley. (2014) Randomised controlled trial of Tumour necrosis factor inhibitors Against Combination Intensive Therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews. Health Technology Assessment 18:66, pages 1-164.
Crossref
Crossref
Johanna Grossman & Steven M. Chamow. 2014. Therapeutic Fc‐Fusion Proteins. Therapeutic Fc‐Fusion Proteins
255
282
.
Robin Christensen, Simon Tarp, Daniel E Furst, Lars E Kristensen & Henning Bliddal. (2013) Efficacy and safety of infliximab or adalimumab, versus abatacept, in patients with rheumatoid arthritis: ATTEST–AMPLE network randomized trial. International Journal of Clinical Rheumatology 8:6, pages 647-655.
Crossref
Crossref
Florian MP Meier, Marc Frerix, Walter HermannUlf Müller-Ladner. (2013) Current immunotherapy in rheumatoid arthritis. Immunotherapy 5:9, pages 955-974.
Crossref
Crossref
Machaon Bonafede, Kathleen M. Fox, Crystal Watson, Nicole Princic & Shravanthi R. Gandra. (2012) Treatment Patterns in the First Year After Initiating Tumor Necrosis Factor Blockers in Real-World Settings. Advances in Therapy 29:8, pages 664-674.
Crossref
Crossref
Yifei Liu, Eric Q. Wu, Arielle G. Bensimon, Chun-Po Steve Fan, Yanjun Bao, Arijit Ganguli, Mei Yang, Mary Cifaldi & Parvez Mulani. (2012) Cost Per Responder Associated with Biologic Therapies for Crohn’s Disease, Psoriasis, and Rheumatoid Arthritis. Advances in Therapy 29:7, pages 620-634.
Crossref
Crossref
Kalle J. Aaltonen, Liisa M. Virkki, Antti Malmivaara, Yrjö T. Konttinen, Dan C. Nordström & Marja Blom. (2012) Systematic Review and Meta-Analysis of the Efficacy and Safety of Existing TNF Blocking Agents in Treatment of Rheumatoid Arthritis. PLoS ONE 7:1, pages e30275.
Crossref
Crossref
Luis Chara, Ana Sánchez-Atrio, Ana Pérez, Eduardo Cuende, Fernando Albarrán, Ana Turrión, Julio Chevarria, Miguel A Sánchez, Jorge Monserrat, Antonio de la Hera, Alfredo Prieto, Ignacio Sanz, David Diaz & Melchor Alvarez-Mon. (2012) Monocyte populations as markers of response to adalimumab plus MTX in rheumatoid arthritis. Arthritis Research & Therapy 14:4, pages R175.
Crossref
Crossref
I Modesto, M Spinello, F Nicchi & M Cottone. (2011) Certolizumab pegol for the treatment of rheumatoid arthritis. Therapy 8:4, pages 391-402.
Crossref
Crossref
ROBERT LAUNOIS, BERNARD AVOUAC, FRANCIS BERENBAUM, OLIVIER BLIN, ISABELLE BRU, BRUNO FAUTREL, JEAN-MICHEL JOUBERT, JEAN SIBILIA & BERNARD COMBE. (2011) Comparison of Certolizumab Pegol with Other Anticytokine Agents for Treatment of Rheumatoid Arthritis: A Multiple-treatment Bayesian Metaanalysis. The Journal of Rheumatology 38:5, pages 835-845.
Crossref
Crossref
Karen Ellegaard, Robin Christensen, Søren Torp-Pedersen, Lene Terslev, Christian C. Holm, Merete J. Kønig, Peter S. Jensen, Bente Danneskiold-Samsøe & Henning Bliddal. (2011) Ultrasound Doppler measurements predict success of treatment with anti-TNF-α drug in patients with rheumatoid arthritis: a prospective cohort study. Rheumatology 50:3, pages 506-512.
Crossref
Crossref
Devesh Mewar & Anthony G Wilson. (2011) Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors. British Journal of Pharmacology 162:4, pages 785-791.
Crossref
Crossref
Hyunbo Shim. (2011) One target, different effects: a comparison of distinct therapeutic antibodies against the same targets. Experimental and Molecular Medicine 43:10, pages 539.
Crossref
Crossref
Massimo Cugno. (2011) Cardiovascular events and survival in rheumatoid arthritis: effects of anti-tumor necrosis factor-alpha treatment. Translational Research 157:1, pages 6-9.
Crossref
Crossref
David L Scott, Frederick Wolfe & Tom WJ Huizinga. (2010) Rheumatoid arthritis. The Lancet 376:9746, pages 1094-1108.
Crossref
Crossref
R. A. Moore, S. Derry, H. J. McQuay, S. Straube, D. Aldington, P. Wiffen, R. F. Bell, E. Kalso & M. C. Rowbotham. (2010) Clinical effectiveness: An approach to clinical trial design more relevant to clinical practice, acknowledging the importance of individual differences. Pain 149:2, pages 173-176.
Crossref
Crossref
Kevin J. Ruff, Anne Winkler, Robert W. Jackson, Dale P. DeVore & Barry W. Ritz. (2009) Eggshell membrane in the treatment of pain and stiffness from osteoarthritis of the knee: a randomized, multicenter, double-blind, placebo-controlled clinical study. Clinical Rheumatology 28:8, pages 907-914.
Crossref
Crossref
CW Pritchard & AB Hawthorne. (2009) Managing immunosuppression in medical patients. British Journal of Hospital Medicine 70:7, pages 394-398.
Crossref
Crossref
Jasvinder A Singh, Robin Christensen, George A Wells, Maria E Suarez-Almazor, Rachelle Buchbinder, Maria Angeles Lopez-Olivo, Elizabeth Tanjong Ghogomu & Peter Tugwell. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Alberto Alonso-Ruiz, Jose Ignacio Pijoan, Eukene Ansuategui, Arantxa Urkaregi, Marcelo Calabozo & Antonio Quintana. (2008) Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskeletal Disorders 9:1.
Crossref
Crossref
R. Christensen, E.M. Bartels, R.D. Altman, A. Astrup & H. Bliddal. (2008) Does the hip powder of Rosa canina (rosehip) reduce pain in osteoarthritis patients? – a meta-analysis of randomized controlled trials. Osteoarthritis and Cartilage 16:9, pages 965-972.
Crossref
Crossref